First and only oral therapy approved for mild, moderate, and severe plaque psoriasis, and active PsA SEE THE DATA
Plaque Psoriasis
3 INDICATIONS Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. Read more
*Estimates of patients treated reflect global data since launch (Apr 2014-Mar 2023; US=58% of data). Calculations based on observed drug utilization parameters and number of units distributed. Utilization patterns change over time to best represent current markets.
FDA, U.S. Food and Drug Administration; PsA, psoriatic arthritis; TB, tuberculosis.
References: 1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 2. Data on file, Amgen Inc. 3. Otezla® (apremilast) FDA approval letter. March 21, 2014.
The safety profile for Otezla was studied in 5 clinical trials in active PsA 2-5,†
*Patients in the PALACE clinical trials could be treated through 5 years. †The 5 clinical trials included PALACE 1, PALACE 2, PALACE 3, PALACE 4, and ACTIVE.
‡Long-term exposure includes apremilast Phase 3 data pool in
the apremilast exposure period from week 0 through 5 years.
§Estimates of patients treated reflect global data since
launch
(Apr 2014-Mar 2023;
US=58% of data).
Calculations based on observed drug utilization parameters and number of units distributed. Utilization patterns change over time to best represent current markets.
‡Long-term exposure includes apremilast Phase 3 data pool in the apremilast exposure period from week 0 through 5 years. §Estimates of patients treated reflect global data since launch (Apr 2014-Mar 2023; US=58% of data). Calculations based on observed drug utilization parameters and number of units distributed. Utilization patterns change over time to best represent current markets.
THE LONG-TERM SAFETY PROFILE OF OTEZLA WAS CONSISTENT THROUGH 5 YEARS OF EXPOSURE IN PALACE 1-4 1,2
PsA, psoriatic arthritis.
Contraindications
Otezla is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulationWarnings and Precautions
Hypersensitivity: Hypersensitivity reactions, including angioedema and anaphylaxis, have been reported during postmarketing surveillance. If signs or symptoms of serious hypersensitivity reactions occur, discontinue Otezla and institute appropriate therapyContraindications
Warnings and Precautions
Adverse Reactions
Use in Specific Populations
Please click here for the full Prescribing Information.
Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for
phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
References: 1. Data on file, Amgen Inc. 2. Kavanaugh A, Gladman DD, Edwards CJ, et al. Arthritis Res Ther. 2019;21(1):118. 3. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 4. Nash P, Ohson K, Walsh J, et al. Ann Rheum Dis. 2018;77(5):690-698. 5. Wells AF, Edwards CJ, Kivitz AJ, et al. Rheumatology (Oxford). 2018;57(7):1253-1263. 6. Otezla® (apremilast) FDA approval letter. March 21, 2014.